Form 4: Jasper Therapeutics COO Acquires 50,000 Stock Options

Jeetinder Singh Mahal, Chief Operating Officer of Jasper Therapeutics, acquired 50,000 stock options on February 13, 2025, according to a Form 4 filing with the SEC.

Summary

• Jeetinder Singh Mahal, the Chief Operating Officer of Jasper Therapeutics, Inc. (JSPR), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on February 13, 2025, where Mahal acquired 50,000 stock options.
• These options have an exercise price of $6.20.
• The options vest over time, with 1/4th vesting on February 13, 2026, and the remaining 1/48th vesting monthly thereafter, contingent upon continuous service.
• The options expire on February 13, 2035.
• Following the reported transaction, Mahal directly owns 50,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock option grants to a company executive. It doesn't inherently indicate positive or negative performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• The acquisition of stock options by the COO aligns his interests with those of the shareholders, as the value of the options is tied to the company's stock performance.

Key Dates